HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

December 10-14, 2019; San Antonio, Texas
In patients with HER2+ MBC and previous treatment with trastuzumab, pertuzumab, and T-DM1, tucatinib in combination with trastuzumab and capecitabine substantially extended survival outcomes compared with trastuzumab and capecitabine alone, including in patients with brain metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 306 KB
Released: December 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Expert-authored commentary on strategies for rethinking breast cancer clinical trial practices during the COVID-19 pandemic from Clinical Care Options (CCO)

Hope S. Rugo, MD Released: September 28, 2020

Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic

Hope S. Rugo, MD Released: September 25, 2020

Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: September 23, 2020

Read this commentary from Clinical Care Options to gain expert perspectives on PARP inhibition in early, metastatic, and triple-negative breast cancer.

Mark E. Robson, MD Released: September 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue